Shanghai Canature Environmental

Companies listed on the Shenzhen Stock Exchange have recently been disclosing progress on buybacks and share purchases at a rapid pace. Since July, a total of 478 announcements on buybacks and share purchases have been made, with 147 new plans added. The combined upper limit for planned share purchases and buybacks has reached 69.306 billion yuan. Sanhuan Group completed an 895 million yuan buyback on July 30 and immediately launched a new buyback plan worth between 500 million and 1 billion yuan. Wangsu Science and Technology plans to spend 300 million to 600 million yuan on share buybacks and cancel all repurchased shares. Sanhua Intelligent Controls completed its first buyback of nearly 100 million yuan. Qu Jianguo, the actual controller of Canature Health, proposed spending 25 million to 50 million yuan on buybacks. Sieyuan Information launched a buyback plan of 30 million to 60 million yuan. Five senior executives, including Hou Zhenfu, chairman of Guangzhi Technology, plan to increase their shareholdings by a combined upper limit of 22 million yuan. Xinghui New Materials has cumulatively repurchased 2.1367 million shares, with a transaction value of approximately 80.6584 million yuan. Industry insiders say the intensive buybacks and share purchases are both a rational response to valuation levels and are expected to further bolster investor confidence.

Canature Health's wholly-owned subsidiary Shanghai Yuantian Biotechnology has officially signed a technical service entrustment contract with Boji Medical, marking the formal entry of YT001 Injection, a Class 1 biologic new drug independently developed by Yuantian Biotechnology for knee osteoarthritis, into the clinical trial stage. YT001 Injection received implied clinical trial approval from the Center for Drug Evaluation of the National Medical Products Administration in October 2024, intended for the treatment of knee osteoarthritis, which has a symptomatic prevalence rate of 8.1 percent in China. Traditional treatment options have shown limited efficacy for some patients, and no cell-based therapy has been approved domestically for knee osteoarthritis. Under the agreement, Boji Medical will serve as the full-process contract research organization, responsible for organizing and implementing the Phase I and Phase II clinical studies of YT001 Injection as well as full-process quality management. Founded in 2016, Yuantian Biotechnology was originally a project company incubated by Yuanneng Cell Technology Group, which was wholly established by Canature Health, and was merged into the listed company system at the end of last year. It is the core subsidiary of the company's cell business segment.

Canature Health announced that as of now, the company has received cumulative US tariff refunds of USD 4.5493 million, including tax refunds of USD 4.3747 million and interest of USD 174,600. Converted at the central parity rate of the RMB exchange rate on July 10, 2026, it is expected to impact the company's net profit attributable to shareholders of the parent by RMB 11.5064 million, accounting for 20.54% of the company's most recent audited net profit attributable to shareholders of the listed company.